CORRIGENDUM
Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results
Adel El Sayed1, *, Abd El-Monim Hilal2, Ahmed Abogamal3, Alaa Labeeb4, Amin Abdel Hamid3, Amira El Gerby2, Ayman Farouk Darwish5, Aziza Sayed Omar6, Dahlia Abdel Mohsen7, Dalia Faiez1, A M Abda8, Fatemah A. Elshabacy9, Manal Tayel10, Mohamed Elwakd11, Mohamed Mortada12, Mohsen H.Elshahaly6, Nevine Mohannad10, Raga A. Kader2, S. Z. Hassan11, Samah A. Elbakry7, Sherif Refaat13
Article Information
Identifiers and Pagination:
Year: 2019Volume: 13
First Page: 85
Last Page: 85
Publisher ID: TORJ-13-85
DOI: 10.2174/1874312901913010085
Article History:
Received Date: 29/07/2018Revision Received Date: 23/10/2018
Acceptance Date: 19/12/2018
Electronic publication date: 30/08/2019
Collection year: 2019
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results
The Open Rheumatology Journal, 2018, 12: 323-331
The last paragraph on page 327 is revised as follows:
In regards to patients receiving leflunomide as a first-line therapy, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 35.40 ±16.49 at baseline visit to reach 15.04 ±9.63 after 6 weeks from treatment initiation. After additional 6 weeks, further significant decrease (p=0.028) was observed in the mean ±SD CDAI total score to reach 11.83 ±5.88.
The original paragraph provided is mentioned below:
In regards to patients receiving leflunomide as a first-line therapy, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 35.40 ±16.49 at baseline visit to reach 15.04 ±9.63 after 6 weeks from treatment initiation, however after additional 6 weeks, the mean ±SD CDAI total score was insignificantly decreased (p=0.028) to be 11.83 ± 5.88.
The first paragraph on page 328 is revised as follows:
In a similar pattern, in patients receiving leflunomide as add-on therapy to other DMARDs with or without steroids, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 37.09 ±14.12 at baseline visit to reach 20.42 ±9.36 after 6 weeks from treatment initiation, and it was significantly further decreased (p<0.001) to reach 15.98 ±10.32 after additional 6 weeks.
The original paragraph provided is mentioned below:
In patients receiving leflunomide as add-on therapy to other DMARDs with or without steroids, the mean ±SD CDAI total score was significantly decreased from 37.09 ±14.12 at baseline visit to reach 20.42 ±9.36 after 6 weeks from treatment initiation. Unlike patients receiving leflunomide as a first line therapy, in this group, the mean ±SD CDAI total score was significantly further decreased to reach 15.98 ±10.32 after an additional 6 weeks.